Key Takeaways
- • The U.S. life sciences real estate sector has emerged as a top-performing alternative asset class over the past decade, driven by sustained demand for high-quality R&D laboratories and manufacturing facilities from biotechnology, pharmaceutical, and medical device companies.
- • Life sciences real estate has delivered superior risk-adjusted returns compared to other major commercial real estate asset types and broader investment categories, establishing institutional credibility among sophisticated capital allocators.
- • The sector's growth has been fueled by structural demand from high-growth biotech and corporate biopharma industries, with property acquisitions and new development activity concentrated in core markets: Boston-Cambridge, San Francisco Bay Area, and San Diego.
- • Capital allocation to life sciences real estate spans institutional investors, international capital, and large private investors, reflecting the asset class's maturation and attractive risk-return profile for alternative investment portfolios.
- • Market dynamics include expanding cap rates (climbing from 4.4% in early 2022 to 6.6% in the most recent quarter) and moderating acquisition activity in 2025, signaling market normalization after pandemic-era capital inflows.
Summary
The U.S. life sciences real estate sector has solidified its position as a premier alternative asset class over the past decade, according to CBRE's comprehensive investment trends analysis released June 11, 2024. Institutional investors have increasingly allocated capital to life sciences properties, driven by structural demand from biotechnology, pharmaceutical, and medical device companies requiring specialized research and development facilities and manufacturing spaces that meet complex regulatory and operational requirements.
Life sciences real estate has outperformed broader commercial real estate categories and other major asset types on a risk-adjusted basis, delivering returns that have exceeded investor expectations. This performance trajectory reflects both pandemic-era capital concentration in life sciences innovation and the sector's fundamental appeal tied to long-term secular growth in biotech and biopharma industries. The sector's resilience stems from high barriers to entry, long-term tenant commitments, and the irreplaceable nature of specialized laboratory and manufacturing infrastructure.
Investment activity has concentrated in established core markets—Boston-Cambridge, San Francisco Bay Area, and San Diego—where biotech ecosystems, venture capital networks, and regulatory infrastructure create competitive advantages. However, CBRE's analysis indicates that established real estate operators have begun targeting secondary markets as primary gateway markets face supply constraints and pricing pressures. The investor base includes institutional capital, international investors, and large private real estate platforms seeking exposure to high-growth life sciences clusters.
Recent market conditions reflect normalization following years of pandemic-driven inflows. Cap rates have expanded significantly, rising from 4.4% in early 2022 to 6.6% in the most recent quarter, indicating both rising discount rates and moderating pricing enthusiasm. Property acquisition activity remained sluggish in the first half of 2025, suggesting investors are recalibrating return expectations and underwriting standards after years of aggressive capital deployment.
CBRE's four-part framework—examining investor landscapes, investment performance, investment characteristics (including ESG considerations and partnership structures), and sector outlook—provides institutional investors with comprehensive guidance on positioning within life sciences real estate. The analysis underscores that while sector fundamentals remain intact, capital allocation decisions increasingly hinge on market-specific dynamics, tenant credit quality, and long-term visibility into biotech funding cycles.
Life sciences real estate has outperformed broader commercial real estate categories and other major asset types on a risk-adjusted basis, delivering returns that have exceeded investor expectations. This performance trajectory reflects both pandemic-era capital concentration in life sciences innovation and the sector's fundamental appeal tied to long-term secular growth in biotech and biopharma industries. The sector's resilience stems from high barriers to entry, long-term tenant commitments, and the irreplaceable nature of specialized laboratory and manufacturing infrastructure.
Investment activity has concentrated in established core markets—Boston-Cambridge, San Francisco Bay Area, and San Diego—where biotech ecosystems, venture capital networks, and regulatory infrastructure create competitive advantages. However, CBRE's analysis indicates that established real estate operators have begun targeting secondary markets as primary gateway markets face supply constraints and pricing pressures. The investor base includes institutional capital, international investors, and large private real estate platforms seeking exposure to high-growth life sciences clusters.
Recent market conditions reflect normalization following years of pandemic-driven inflows. Cap rates have expanded significantly, rising from 4.4% in early 2022 to 6.6% in the most recent quarter, indicating both rising discount rates and moderating pricing enthusiasm. Property acquisition activity remained sluggish in the first half of 2025, suggesting investors are recalibrating return expectations and underwriting standards after years of aggressive capital deployment.
CBRE's four-part framework—examining investor landscapes, investment performance, investment characteristics (including ESG considerations and partnership structures), and sector outlook—provides institutional investors with comprehensive guidance on positioning within life sciences real estate. The analysis underscores that while sector fundamentals remain intact, capital allocation decisions increasingly hinge on market-specific dynamics, tenant credit quality, and long-term visibility into biotech funding cycles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.